Lumito reports positive results from ongoing collaborative research projects – SCIZYS demonstrates high sensitivity across multiple applications
Lumito AB (publ) ("Lumito" or the "Company") today announces positive results from ongoing collaborative projects with external researchers, further strengthening the evidence supporting the Company's tissue analysis platform, SCIZYS. In a pilot project conducted together with Professor Anders Bjartell at Lund University, SCIZYS successfully identified the biomarker PSA in lymph node tissue from prostate cancer. […]
Lumito’s founder and Board member Stefan Andersson-Engels presented at the prestigious Gordon Research Conference 2026
Lumito AB (publ) ("Lumito" or the "Company") announces today tha Company’s founder and Board member Stefan Andersson-Engels has participated as an invited speaker at the prestigious conference Optics and Photonics in Medicine and Biology Gordon Research Conference (GRC) 2026. During the conference, Stefan Andersson-Engels presented the lecture "Illuminating Biology Across Scales: Upconverting Nanoparticles as Background-Free […]
Lumito and Offspring Biosciences report promising initial results from pilot study evaluating automated immunohistochemistry platform
Lumito AB (publ) ("Lumito" or the "Company") and Offspring Biosciences Sweden AB ("Offspring Biosciences") today announce promising initial results from the pilot study evaluating Lumito's proprietary tissue labelling and high-sensitivity imaging platform in combination with Offspring Biosciences' automated Immunohistochemistry (IHC) platform. Offspring Biosciences has transferred Lumito's SCIZYS Erbium manual assay on to the Dx Ultra […]
Lumito and Navinci initiate pilot project – promising initial results from evaluation of combined technology
Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company has initiated a pilot project together with the Swedish biotech company Navinci Diagnostics AB (”Navinci”) to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis. The pilot project aims to combine Lumito’s high-sensitivity image analysis platform with Navinci’s in […]
Lumito appoints Pascal Bamford as new Chair of the Scientific Advisory Board
Lumito AB (publ) ("Lumito" or the "Company") today announces that Pascal Bamford has been appointed Chair of the Company’s Scientific Advisory Board (SAB). He succeeds Paul Waring, who will continue to serve as a trusted advisor and remain closely engaged with Lumito going forward. The change reflects Lumito’s transition into an increasingly commercial phase, where […]
Lumito to present two scientific posters and exhibit at the European Congress of Pathology 2026 in Stockholm
Lumito AB (publ) ("Lumito" or the "Company") today announces that two scientific abstracts have been accepted for poster presentation at the European Congress of Pathology 2026, taking place at Stockholmsmässan, Stockholm, Sweden, on September 12-16, 2026. The Company will also participate as an exhibitor at the congress, which is one of the largest international meetings […]
Subscription price for the exercise of warrants of series TO7 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026
Lumito AB (publ) (“Lumito” or the “Company”) issued warrants of series TO7 in connection with a rights issue during the fourth quarter of 2025. Five hundred (500) warrants entitle the holder to subscribe for one (1) new share in the Company. The subscription price for the warrants of series TO7 was set at 70 percent […]
Simpler biomarker workflows without compromising sensitivity: new white paper shows how researchers gain reproducible, quantitative IHC results in fewer steps
Lumito AB (publ) (“Lumito”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce the publication of a new white paper demonstrating how researchers can simplify immunohistochemistry (IHC) workflows while maintaining high sensitivity, quantitative robustness, and reproducibility. The study shows that direct labelling of biomarkers when combining Lumito’s SCIZYS platform with Atlas Antibodies’ well‑characterised primary antibodies can […]
Lumito’s CRO strategy generates revenue through collaboration with Truly Labs AB
Lumito AB (publ) (“Lumito” or the “Company”) today announces that its collaboration with Truly Labs AB (“Truly Labs”) has generated its first revenue linked to a customer project within the pharmaceutical industry. The project was conducted by Truly Labs for a global pharmaceutical client, where Lumito’s SCIZYS platform was used to analyse rare cells in […]
Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis
Lumito AB (publ) (“Lumito” or the “Company”) and OracleBio (“OracleBio”) today announce that a joint pilot project has been initiated. The purpose of the project is to explore the combination of Lumito’s high-sensitivity platform for tissue labelling and digital imaging with OracleBio’s expertise in quantitative image analysis. The pilot project is fully aligned with Lumito’s […]